Document Detail


Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer.
MedLine Citation:
PMID:  17566667     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the suppression of normal hematopoiesis, chemotherapy is currently the most used method to treat AML. The standard chemotherapy results in a more than 50% complete remission rate in AML patients. However, treatment with drugs such as anthracyclines is associated with severe side effects and a high incidence of relapse, the long-term survival of AML is poor. The success of the treatment of acute promyelocytic leukemia with all trans retinoic acid and chronic myeloid leukemia with imatinib mesylate (Gleevec) has led to increased efforts to look for agents for AML targeted therapy. But, most of presented targeted therapy agents do only direct some oncogenic molecules involved in the leukemogenesis of AML, their anti-leukemic efficacy is unsatisfied. Thus, novel therapeutic approaches are required. In recent years, a leukemia stem cells (LSCs) origin for AML has been demonstrated, and some unique immunophenotype and specific molecular features of LSCs have also been identified. With the technique development of Immunoliposomes (antibody-coupled liposomes) and the recombination of the variable regions of heavy and light chains and their integration into a single polypeptide that offer the possibility of using single-chain antibody variable region fragments (scFv) for targeting purposes, here we put the hypothesis that treatment of AML by targeting both LSCs and oncogenic molecule participated in AML pathogenesis, with LSCs-specific scFv-immunolipoplexes as a deliverer, might be possible. If successfully using this approach in practice, LSCs might be selectively eradicated and AML might be cured.
Authors:
Guang Ping Wang; Zhen Hua Qi; Fang Ping Chen
Related Documents :
17321987 - Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarab...
20810927 - Pan-histone deacetylase inhibitor panobinostat depletes cxcr4 levels and signaling and ...
12075547 - The use of cytochemistry, immunophenotyping, flow cytometry, and in vitro differentiati...
18445657 - Stromal-mediated protection of tyrosine kinase inhibitor-treated bcr-abl-expressing leu...
12917627 - Genetic rescue of cdk4 null mice restores pancreatic beta-cell proliferation but not ho...
2476957 - Histochemical comparison of mast cells obtained from the airways of mongrel dogs and ba...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-06-12
Journal Detail:
Title:  Medical hypotheses     Volume:  70     ISSN:  0306-9877     ISO Abbreviation:  Med. Hypotheses     Publication Date:  2008  
Date Detail:
Created Date:  2007-12-06     Completed Date:  2008-04-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  122-7     Citation Subset:  IM    
Affiliation:
Department of Hematology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China. guangpingw@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Immunoglobulin Fragments / immunology*
Immunoglobulin Variable Region / immunology*
Leukemia, Myeloid, Acute / immunology,  therapy*
Neoplasm Proteins / physiology*
Stem Cell Transplantation*
Stem Cells / pathology*
Chemical
Reg. No./Substance:
0/Immunoglobulin Fragments; 0/Immunoglobulin Variable Region; 0/Neoplasm Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications f...
Next Document:  Central corneal thickness as a risk factor for glaucoma.